SUMM.L Share News (SUMM)
SUMM Share
SUMM Share
SUMM Share
SUMM Share
SUMM
SUMM Share
SUMM Broker
SUMM Directors
SUMM Financial
SUMM
SUMM Short
SUMMMon, 18th Nov 2013 08:10
LONDON (Alliance News) - Drug company Summit Corporation PLC Wednesday said its loss widened in its last financial year as its research and development costs rose as both its drug programmes moved towards clinical trials. The Oxford-based company is currently developing treatments for Duche
Read moreLONDON (Alliance News) - Summit Corporation PLC Tuesday said the US Food and Drug Administration has approved its Investigational New Drug application to initiate a Phase 2 proof of concept study for its novel antibiotic SMT19969 for the treatment of C. difficile infection. In a statement,
Read moreLONDON (Alliance News) - Summit Corporation Wednesday said it raised gross proceeds of GBP1.0 million in an oversubscribed subscription offer, meaning it raised GBP22.0 million through its recent placing and the subscription. In a statement, Summit said it had to scale back allocations afte
Read moreDecent gains from AstraZeneca and Shire gave the pharmaceuticals sector a boost on Tuesday as both firms gave confident outlooks. At the JP Morgan Healthcare Conference in San Francisco, AstraZeneca Chief Executive Pascal Soriot said he expects the company to return to growth sooner than analysts c
Read moreAggreko: RBC Capital reduces target price from 1850p to 1680p, while its neutral rating remains unchanged. Aviva: JP Morgan raises target price from 393p to 436p and retains an overweight rating. BHP Billiton: Canaccord Genuity takes target price from 1950p to 2050p maintaining a hold recommendati
Read moreAberdeen Asset Management: Bank of America reduces target price from 410p to 360p maintaining an underperform rating. ARM Holdings: UBS upgrades to buy from neutral, keeps target price at 970p. Cineworld: Investec ups target price from 347p to 360p and keeps a buy recommendation. N+1 Singer moves
Read moreAIM-listed biotech group Summit Corporation has narrowed the focus of its research programmes to two key assets, which both made encouraging progress in clinical trials, the company said. Chief Executive Glyn Edwards, who was appointed in April last year, curtailed other research activities to pre
Read moreShares in AIM-listed drug development company Summit rose on Monday after the company unveiled encouraging results from a study investigating the impacts of a treatment on neurodegenerative diseases. The company reported that it had presented new data from its OGA (O-linked N-acetylglucosaminidase
Read moreSummit Corp., an AIM-listed drug discovery and development company, has formed an advisory board to support the scientific and clinical development of its utrophin modulator programme for the treatment of the fatal genetic disease Duchenne Muscular Dystrophy (DMD). The board will be made up of six
Read moreSummit, a UK drug discovery company, said it had been awarded four million pounds to support clinical development of a new C. difficult antibiotic The money from charitable foundation the Wellcome Trust will be used to develop Summit's SMT 19969 drug through to clinical proof of concept studies.
Read moreShares in drug developer Summit Corporation rocketed on Wednesday after it announced positive results in tests for its new Duchenne Muscular Dystrophy (DMD) drug. DMD is a fatal muscle wasting disease for which there is currently no cure. The firm announced positive top-line results from a Phase 1
Read moreUK drug discovery company Summit has signed a technology licensing agreement with US pharmaceuticals colossus, Bristol-Myers Squibb. The US firm will use use Summit's proprietary Seglin technology to identify and develop drug candidates for up to ten targets across multiple therapeutic areas. Summi
Read more
